Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Evotec SE

Comparing R&D Priorities: Regeneron vs. Evotec

__timestampEvotec SERegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014124040001271353000
Thursday, January 1, 2015183430001620577000
Friday, January 1, 2016181080002052295000
Sunday, January 1, 2017176140002075142000
Monday, January 1, 2018356190002186100000
Tuesday, January 1, 2019584320003036600000
Wednesday, January 1, 2020639450002735000000
Friday, January 1, 2021722000002908100000
Saturday, January 1, 2022766420003592500000
Sunday, January 1, 2023575190004439000000
Monday, January 1, 20245132000000
Loading chart...

Igniting the spark of knowledge

Innovation in Pharmaceuticals: A Comparative Analysis

In the ever-evolving world of pharmaceuticals, innovation is the key to staying ahead. Regeneron Pharmaceuticals, Inc. and Evotec SE are two companies that have consistently prioritized research and development (R&D) over the past decade. From 2014 to 2023, Regeneron has demonstrated a robust commitment to innovation, with R&D expenses growing by approximately 250%, reaching a peak in 2023. In contrast, Evotec SE, while showing a steady increase, has seen its R&D spending grow by about 360% over the same period. This stark difference highlights Regeneron's significant investment in innovation, with its R&D expenses consistently dwarfing those of Evotec SE. As the pharmaceutical landscape continues to evolve, these investments in R&D are crucial for developing groundbreaking treatments and maintaining competitive advantage.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025